ERBB2 and breast cancer: The goal of this study was to evaluate the in vitro and in vivo characteristics of IRDye800-labeled trastuzumab and pertuzumab in breast cancer cell lines and xenografts with varying HER2 expression levels as a prelude to clinical studies.